STAA · STAAR Surgical Company

Current Thesis

STAAR Surgical makes the EVO/EVO+ ICL (Implantable Collamer Lens) an implantable myopia-correction lens positioned as a refractive-surgery alternative to LASIK, with revenue heavily levered to China. The trade here is a post-merger-break special situation, not an accelerating-narrative momentum leg. Alcon agreed to buy STAAR at $28 (Aug 2025), bumped to $30.75 (≈74% premium to 90-day VWAP), but shareholders rejected the deal at the Jan 6 2026 special meeting; the merger was terminated. Broadwood Partners (~31.1% holder) led the revolt, secured three board seats, and argues a standalone path toward ~$50. The standalone story is genuinely inflecting Q1 2026 (reported May 13) net sales $93.5M, +119.6% YoY, non-GAAP EPS $0.29 vs $0.08 consensus, a swing to +$5.2M net income from a -$54.2M loss a year prior, driven by the EVO+ launch in China. The live driver, though, is the June 18 2026 standstill expiry + virtual annual meeting an event-binary. The tape faded from the $35.87 52-week high / $32.01 (May 14) to ~$28 (early June), recovered to ~$30 (Jun 5), and the consensus price target (~$27.81) now sits below spot. The $40 (Wedbush) and $50 (Broadwood) upside cases are M&A/activist-contingent, not organic. This is a low-conviction probe at the edge of the narrative-velocity playbook.

Bull Case

• Q1 2026 (May 13): net sales $93.5M, +119.6% YoY. Non-GAAP EPS $0.29 crushed $0.08 consensus; net income swung to +$5.2M from -$54.2M a year prior. China contributed $47.4M (just over half of total), with the Americas posting continued double-digit growth and rest-of-world +6%.
• Channel looks cleaner than the 2025 destocking trough. Management stated (May 13 call) that China inventory entered Q1 normalized and aligned with contractual targets, and that sales grew while inventory was held flat to slightly down the opposite of the sell-in pull-forward that broke the stock in 2025.
• Activist floor: Broadwood owns ~31.1% and keeps buying. Q1 2026 purchase of ~1.1M shares (~$21M, filed ~May 14; flagged in a June 1 2026 Motley Fool note on the 13F), on top of discrete 2026 tranches. A 31% holder accumulating into strength is a hard conviction signal.
• M&A optionality re-arms June 18 2026. Under the Jan 15 2026 cooperation agreement, Broadwood's standstill (no demand to call a special meeting) expires June 18 the same day as the annual meeting. Post-expiry, the activist bloc can press a renewed sale process. ISS called the original Alcon process "deeply flawed" and noted the board dismissed interest from multiple parties while relying on a single bidder so latent buyer interest may exist. Wedbush reiterated Outperform, $40 PT (May 29 2026).
• Tariff overhang being engineered out. Management guided to supplying all China EVO/EVO+ from Switzerland by end-2026, removing US-tariff exposure on the China book. 2026 spend framed near $225M with gross margins near 75%.

Bear Case

• The momentum is already spent. From $35.87 (52-wk high) and $32.01 (May 14) down to ~$28 (early June), now ~$30. Consensus PT (~$27.81) sits below spot, and the dispersion is wide ($13 low to $40 high). The bullish $40/$50 cases are entirely M&A/activist-contingent; if June 18 passes without a renewed process, that premium deflates.
• China concentration remains the structural risk. China was >50% of Q1 sales. Prior-quarter dynamics flagged China distributors running a higher share of trade receivables than of revenue a collectability/sell-in watch item. The exact China-ICL destocking dynamic took the stock to a $15.59 low within the past year.
• +119.6% YoY is a base effect, lapping a collapsed Q1 2025 not proof of a new secular ramp. Management declined to give formal full-year revenue guidance, citing macro/currency/geopolitical uncertainty. Sequential durability is unproven until the next print (~early Aug).
• Leadership is interim. Co-CEOs Warren Foust (President/COO) and Deborah Andrews (CFO) have run the company since Feb 1 2026, with a permanent-CEO search open. A standalone value-creation plan executed by an interim team is a weaker thesis than a binding bid.
• Anchoring to the dead $30.75 deal or Broadwood's $50 is the trap. "It will get bought again" is a hope, not a setup. No binding bid exists today, and the consensus analyst stands below the current quote.

Setup & Price Structure

• Spot ~$29.99 (Jun 5 2026). 52-wk range $15.59–$35.87. Market cap roughly ~$1.45–1.5B.
• Structurally mid-range and choppy rather than stretched or blown off: below the May $32–$35.87 shelf, holding above the ~$26 post-Q1 consolidation zone and a rising 200-day. The early-June dip to ~$28 was bought back toward $30 ahead of the meeting consistent with event-positioning, not a fresh momentum impulse.
• No clean trend leg to ride. The chart is a binary-event coil into June 18, with the consensus analyst below spot and the upside targets contingent on corporate action. RSI is unremarkable there is no overbought blowoff to fade and no breakout to chase.
• Analyst grid (2026): Wedbush $40 Outperform (May 29); Piper Sandler $33 Neutral (May 14); Canaccord $32 Buy (May 14); Stifel $31 Hold (May 14); Wells Fargo $25 (May 15). Consensus rating "Hold," consensus PT ~$27.81.

Catalyst Calendar (next 30 days)

• 2026-06-18 Virtual 2026 annual meeting + Broadwood standstill expiry (THE event). Shareholders vote to elect seven directors (slate includes Broadwood's Neal Bradsher and Richard LeBuhn, plus Yunqi Capital's Christopher Wang), add 3.9M shares to the equity incentive plan, ratify BDO USA as auditor, and an advisory say-on-pay vote. Standstill lapses the same day, re-arming the activist's ability to demand a special meeting / push a renewed sale process.
• ~2026-06 (ongoing) Form 4 / 13D-A watch. Any further Broadwood accumulation into the meeting would reinforce the activist-floor read; a pause or trim would weaken it.
• ~early-Aug 2026 (est.) Q2 print. Not in the 30-day window but the decisive read on whether China is a durable ramp or a base-effect bounce. Confirm exact date on investors.staar.com before any blackout-window sizing.

What Would Change Our Mind

• Bullish re-rate: A renewed strategic review / sale-process announcement at or after June 18, or a fresh ≥$30.75 indication of interest from a strategic acquirer, would convert this from coil to event leg. A clean reclaim of the $32–$35.87 shelf on volume, with Broadwood still buying, would mark a genuine standalone re-rate.
• Thesis break: A weekly close below ~$26 (loss of the post-Q1 consolidation floor and rising 200-day) signals the activist/M&A premium bleeding out. June 18 passing with no renewed sale-process or strategic-review language, followed by a loss of $28 support, would confirm the special-situation premium is gone. A Q2 print (~early Aug) showing China revenue declining sequentially with trade-receivables share rising again would re-open the 2025 destocking risk and break the recovery story.

Correlation Notes

• China-consumer / discretionary-medtech beta. The dominant swing factor is China refractive demand and channel health, not a US sector theme STAAR trades on China consumer recovery, RMB/FX, and tariff headlines more than on broad medtech (ISRG, ALC, COO) tape. EVO+ adoption curves and Chinese myopia-surgery volumes are the real inputs.
• Alcon (ALC) read-through. As the spurned acquirer that bid twice, Alcon's stance is a standing optionality variable; renewed strategic interest from any large ophthalmic player would be the M&A trigger.
• Idiosyncratic, low index correlation. Price action is dominated by the Broadwood activist position and the binary June 18 calendar, so the name behaves more like an event/merger-arb situation than a momentum-correlated equity. It will not move with an accelerating-narrative basket; it moves on corporate action and the next China print.